Gene Therapy for Longevity

Gene therapy for longevity, delivering genes such as follistatin or klotho via plasmid or viral vectors to alter muscle, metabolic, or cognitive aging pathways, exists today almost entirely outside the FDA-regulated trial system, offered commercially in jurisdictions with looser biomedical oversight.

The most visible commercial provider is Minicircle, which offers a follistatin gene therapy through clinics in Roatan, Honduras, at roughly $25,000 per dose. Fortune's 2023 investigation reported unpublished trial data on 44 people aged 23 to 89 claiming an average reduction of roughly 11 years in a measured 'genetic age,' and quoted an unnamed scientist warning the approach 'will kill someone' [1]. Minicircle operates in Prospera, Honduras, a special economic zone with reduced regulatory requirements, and its funders and clients reportedly include prominent technology and biohacking figures [2].

The featured counter-finding is the company's own data. Minicircle's own preprint, describing a trial of 43 people, reported that extrinsic epigenetic age actually increased significantly following treatment, the opposite of the intended direction, while intrinsic epigenetic age trended downward but not to a statistically reliable degree, DunedinPACE (a pace-of-aging clock) showed no clear change, and telomere length trended toward increase without reaching a clearly established effect [3]. A company's own published data showing its flagship product moved a key aging marker in the wrong direction is a rare and unusually candid counter-finding, and it directly undercuts marketing claims of clean, unambiguous rejuvenation.

Independent experts have been publicly skeptical of the underlying gene-delivery technology itself, beyond this one company's results. Stanford's Mark Kay, a co-inventor of the minicircle DNA delivery technique the company is named after, has stated that human studies using this delivery method have failed to reliably get DNA into the cell nucleus where it needs to act [4]. Scott Harper of Nationwide Children's Hospital has stated more broadly that nothing in this class of gene therapy has proven to work in human clinical trials the way it does in animal models [4]. A broader review of CRISPR and gene therapy approaches to age-related neurodegenerative disease similarly describes the field as still preclinical and early-stage for aging-specific applications generally [5].

Who this does not work for, or where the evidence is weakest: this is not a treatment offered through any peer-reviewed, FDA- or EMA-regulated clinical trial; it is a direct-to-consumer commercial product administered in a jurisdiction chosen specifically for its lighter regulatory environment. Anyone considering it should treat the company's own preprint, which shows a key marker moving in the wrong direction, as more informative than the marketing materials built around the unpublished 44-person dataset. People with any underlying health condition face unknown and untested risk from an intervention that has not been through standard phase 1-3 safety and efficacy testing. The specific gene-delivery technology's core nuclear-uptake problem, as described by one of its own co-inventors, is a fundamental technical concern, not a minor implementation detail.

Mechanistically, follistatin is proposed to inhibit myostatin, a muscle-growth inhibitor, plausible for increasing muscle mass, and klotho is linked to several anti-aging pathways in animal models, but delivering these genes effectively and safely into human cells at scale remains the central unsolved problem the field's own experts identify.

Plain takeaway: commercial gene therapies for longevity currently operate almost entirely outside regulated clinical trials, in jurisdictions chosen for lighter oversight, and the clearest evidence available, the provider's own preprint data, shows a key epigenetic aging marker moving in the wrong direction rather than confirming the rejuvenation claims used in its marketing; independent experts, including a co-inventor of the underlying delivery technology, have raised fundamental technical doubts about whether this approach reliably works in humans at all.